HAZNEDAROGLU, I. MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML). Mediterranean Journal of Hematology and Infectious Diseases, v. 6, n. 1, p. e2014009, 31 dez. 2013.